Glaxo Exercises License Option for Investigational Cancer Treatment

Features Dow Jones Newswires

GlaxoSmithKline PLC (GSK.LN) has exercised an option to obtain a global license for an investigational cancer treatment therapy.

Continue Reading Below

The pharmaceutical company said Thursday that it will pay up to 48 million pounds ($62.60 million) to Adaptimmune (ADAP) for obtaining a license for investigational SPEAR T-cell receptor therapy for treating NY-ESO-1, a type of cancer tumor.

Glaxo will assume responsibility for all development, manufacturing and commercialization activities for therapy.

Shares of Glaxo at 1143 up 0.1% at 1,508 pence.

Write to Tapan Panchal at

(END) Dow Jones Newswires

Continue Reading Below

September 07, 2017 08:04 ET (12:04 GMT)